Biohaven Ltd.

NYSE:BHVN

Biotechnology

Healthcare
$13.65 -1.62%

-$0.22 today

Market cap
$2.06B
Beta
3.31
P/E (TTM)
-3.1
EPS (TTM)
-$4.39
52W Low $7.48High $18.57

Volume 3.26M

Average 2.47M

Returns on capital

Biohaven Ltd. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-1418.8%

avg 442.2%

ROIC

-218.4%

avg -125.7%

ROA

-163.7%

avg -97.5%

Analysis

ROA is currently the strongest return metric at -163.7% versus its period average of -97.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Vladimir Coric

Chairman & Chief Executive OfficerUSD 1.4M55——

Matthew Buten

Chief Financial OfficerUSD 858.61K65175.00K0.17%

Bruce D. Car DACVP

Chief Innovation OfficerUSD 801.36K64——

Kimberly Gentile

Senior Vice President of Clinical OperationsUSD 757.72K601.00K<0.01%

Warren Volles

General Counsel & Chief Legal Officer————

Clifford Bechtold

President, GM of Biohaven Ireland & Chief Compliance Officer————

George C. Clark

Vice President & Chief Accounting Officer—4150.00K0.05%

John McGill

Chief Technology Officer————

Deb Young

Senior Director of Regulatory Affairs & Operations————

Jennifer Porcelli

Vice President of Investor Relations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 15, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A12 analysts
RevenueN/AN/AN/A
N/A7 analysts
Net IncomeN/AN/AN/A
N/A7 analysts
EBITN/AN/AN/A
N/A7 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Biohaven Ltd. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about BHVN's management, answered from reported figures.

Who manages BHVN?

Biohaven Ltd. (BHVN) lists 10 active executives. The top listed executive is Bruce D. Car DACVP, Chief Innovation Officer.

Are BHVN insiders buying or selling?

Recent insider activity shows net buying of $287.01M.